-+ 0.00%
-+ 0.00%
-+ 0.00%

Shisi Pharmaceutical Group (02005): Ziprasidone mesylate approved as an API for use in marketed formulations

Zhitongcaijing·09/16/2026 09:09:06
Listen to the news

Zhitong Finance App News, Shisi Pharmaceutical Group (02005) announced that the Group's ziprasidone mesylate has been approved by the China National Drug Administration and registered as an active ingredient for use in marketed formulations. Ziprasidone mesylate is mainly used to treat acute symptoms of agitation in patients with schizophrenia.

This approval was granted to further improve the Group's second-generation antipsychotic highly active ingredient (HPAPI) product matrix. At present, the Group has built a leading second-generation anti-psychotic HPAPI platform in China, covering bunanserine, lurasidone, ziprasidone hydrochloride, and the approved ziprasidone mesylate this time, and continues to provide high-quality API supply chain support for domestic pharmaceutical companies.